Effects of Helicobacter Pylori Infection Eradication in Patients With Parkinson's Disease

• Status: Completed
• Trial end date: 2013-04-01
• Target enrollment: 0
• Participant gender: All

Summary

A higher prevalence of Helicobacter pylori infection rate has been demonstrated among PD patients compared to controls. As H. pylori infection is known to interfere with levodopa absorption, we embarked on this is a study to understand the effects of Helicobacter pylori infection eradication among a selected Malaysian population with Parkinsons disease, in relation to levodopa effectiveness and motor improvements.

The study hypotheses are:

1. H. pylori eradication improves L-dopa 'onset' time and prolongs the L-dopa 'on-time' duration.

2. PD patients with H. pylori infection show clinical improvement in motor disability and quality of life after eradication therapy of H. pylori, assessed using UPDRS-III / PDQ39 questionnaires.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National University of Malaysia
• Treatments: Amoxicillin; Clarithromycin; Esomeprazole

Criteria

Inclusion Criteria:

• Diagnosis of idiopathic Parkinson's disease (PD) by a neurologist

• Age more than 18 years

• Written informed consent given either by the patient or next of kin

• Patient on L-DOPA therapy

Exclusion Criteria:

• Patients with a diagnosis of secondary parkinsonism, and Parkinson's plus syndrome

• History of recent proton pump inhibitors (PPIs) or Histamine (H2) antagonist use for at least 4 weeks prior to the urea breath test

• History of recent antibiotics use (less than 6 months)

• Inability to perform urea breath test